Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 1
1971 1
1973 1
1992 1
1995 1
1996 2
2000 2
2002 1
2003 1
2007 2
2008 2
2009 4
2011 1
2015 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
The Rebif new formulation story: it's not trials and error.
Jaber A, Driebergen R, Giovannoni G, Schellekens H, Simsarian J, Antonelli M. Jaber A, et al. Among authors: simsarian j. Drugs R D. 2007;8(6):335-48. doi: 10.2165/00126839-200708060-00002. Drugs R D. 2007. PMID: 17963425 Review.
Attenuated rubella viruses. Laboratory and clinical characteristics.
Meyer HM Jr, Parkman PD, Hobbins TE, Larson HE, Davis WJ, Simsarian JP, Hopps HE. Meyer HM Jr, et al. Among authors: simsarian jp. Am J Dis Child. 1969 Aug;118(2):155-65. doi: 10.1001/archpedi.1969.02100040157001. Am J Dis Child. 1969. PMID: 4978508 No abstract available.
Factors that influence adherence with disease-modifying therapy in MS.
Treadaway K, Cutter G, Salter A, Lynch S, Simsarian J, Corboy J, Jeffery D, Cohen B, Mankowski K, Guarnaccia J, Schaeffer L, Kanter R, Brandes D, Kaufman C, Duncan D, Marder E, Allen A, Harney J, Cooper J, Woo D, Stüve O, Racke M, Frohman EM. Treadaway K, et al. Among authors: simsarian j. J Neurol. 2009 Apr;256(4):568-76. doi: 10.1007/s00415-009-0096-y. Epub 2009 Apr 27. J Neurol. 2009. PMID: 19444532
Safety and immunogenicity of a new formulation of interferon beta-1a (Rebif New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results.
Giovannoni G, Barbarash O, Casset-Semanaz F, King J, Metz L, Pardo G, Simsarian J, Sørensen PS, Stubinski B; Rebif New Formulation Study Group. Giovannoni G, et al. Among authors: simsarian j. Mult Scler. 2009 Feb;15(2):219-28. doi: 10.1177/1352458508097299. Epub 2008 Aug 28. Mult Scler. 2009. PMID: 18755819 Clinical Trial.
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.
O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, Hartung HP, Jeffery D, Kappos L, Boateng F, Filippov V, Groth M, Knappertz V, Kraus C, Sandbrink R, Pohl C, Bogumil T; BEYOND Study Group; O'Connor P, Filippi M, Arnason B, Cook S, Goodin D, Hartung HP, Kappos L, Jeffery D, Comi G. O'Connor P, et al. Lancet Neurol. 2009 Oct;8(10):889-97. doi: 10.1016/S1474-4422(09)70226-1. Epub 2009 Sep 2. Lancet Neurol. 2009. PMID: 19729344 Clinical Trial.
20 results